Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (July 2023)
20 slides from Pulse Biosciences's investor presentation, Jul 20, 2023
Slide 1: Pulse Biosciences Investor Presentation July 2023
(D) Pulse Biosciences: ay Investor Presentation July 2023
Slide 2: Forward Looking Statements
Forward Looking Statements sents inthis presentation that ae not historical are forward-looking statements, including, among other things, statements relating tothe effectiveness ofthe Compun/s SPF tecoeey od Cex pen owen thema eo! el hie Sprng eden once sue, Sateen conceng the Camponys ered sorcere
Slide 3: Powering the next generation in bioelectric medicine with nsPFA technology
Powering the next generation i in bioelectric medicine w ith technology. {O) Pulse Biosciences:
Slide 4: Proven Leadership Team
Proven Leadership Team eo 2 6 @ Kevin Danahy Darrin Uecker Mitch Levinson Dr. Gan Dunnington Chiet Executive Officer ‘Chet Technology Officer & Chiet Strategy Oficer Chiet Medical Officer Director : LTTivE fohwon-ftmon sc 9 @NELLCOR scoosasning them parent os Established Board of Outside scene rears
Slide 5: Proprietary Technology Novel AF nsPFA Devices
Proprietary Technology Novel AF nsPFA Devices ‘Only company bringing novel 1nsPFA enabled appli [Nanosecond Pulsed Feld Ablation {9sPF) technology tothe health care of patients ors deliver highly differentiated value inthe Robust Patent Portfolio Surrounding the tec treatment of AF i Broad Medical D
Slide 6: Plan
PLAN 1 . . 1a} 2015 2016 2017 2018 2019 2020 2021 2022 1 Funaing Secu for Next Commerc ‘plication (OD) Pulse Biosciences:
Slide 7: Addressing the Entirety of the Growing AF Market
Addressing the Entirety of the Growing AF Market Global Atrial Fibrillation AF Patients 2019: (AF) Di State: ~43M Global? >$8B epecnt 2050 Global? Electrophysiology Market Surgical Ablation Catheter Ablation Growing Surgical and >IM Catheter Ablations Hybrid Ablation Market Performed Per Year The sa
Slide 8: Current Ablation Technologies Require a Tradeoff
jecause ceca Ry profiles, physicians must use suboptimal parai in order to. protect anode tissues More pati n be treated, and with b results, aes physicians do not need to trade safety for efficacy PFA devices coming to market use rae designs and off-the- ATCT ally for cardiac carpus not designed sp
Slide 9: Nonthermal modality delivering nanosecond pulses of electrical energy
Nonthermal modality that High speed nanosecond er Unlike thermal (heat/cold) delivers nanosecond duration pulses penetrate the cell membrane modalities, nsPFA directly pulses of electrical energy and disrupt internal cellular impacts cellular structures while ‘function, leading to regulated cell ing
Slide 10: Differentiated Properties of nsPFA Energy Pulses
Differentiated Properties of nsPFA Energy Pulses ‘sPFA uses a nanosecond pulse of higher amplitude and sigifcanty shorter duration Ze Standard PFA uses longer, low amplitude pulses resulting in high total energy delivery Pulse Amplitude Pulse Duration * Nani nd pul nb * Asa result, nsPFA can requir
Slide 11: Advantages of nsPFA Technology
Advantages of nsPFA Technology Eliminating the substantial tradeoff between safety and efficacy Better procedural efficacy than point ablation techniques Better safety profile than current technologies Differentiated Clinical Results More patients can be treated due to faster procedure times Pulse B
Slide 12: Catheter Delivery of Energy — Cardiac Ablation
Catheter livery of Energy — Cardiac Ablation » ig Y Proprietary nsPFA-Optimized 2-Day Endocardial Surface Catheter Design Sem Diameter 'nsPFA Generator Platform (O PusseBiosciences
Slide 13: nsPFA can create clinically relevant circumferential wide lesions
(OD) Pulse Biosciences: nsPFA can create clinically relevant circumferential wide lesions with cine [is muscular stimulat Tolerance/Safety nsPFA can create clinically relevant deep and wide lesions, which did not demonstrate any evidence of thermal injury and delivery was associated with only mild m
Slide 14: between electrode:
between electrode: (©) Pulse Biosciences:
Slide 15: Cardiac Clamp Strategic Opportunity
Cardiac Clamp Strategic Opportunity High Strategic Value 1. Fast and Easy Market Entry. 2. nsPFA Superior Product Offering 3. Ability to Prove Effectiveness for AF Prior to Catheter Launch 4, Provides Complete Solution 5. Si Launch (D) PulseBlosciences: 5 pyicre202 Ann! Report) Oppenheimer Market es
Slide 16: Application Milestones for Treatment of AF
Application Milestones for Treatment of AF 2023 2024 2025 _—___e ____-¢. Surgical * Application ~~ Catheter zz Application = Pilot Launch (OD) Pulse Biosciences:
Slide 17: Developing Strategy for Launch
1: 1 ag re Activities Developing Strategy for launch: © Pre-Launch Narrow-Deep App! *Estabsh KOL network and advisory board (in process) © Pilot “Place Coll systems at regional KOL loca ct ° ioe + Use pilot sitesto learn bes practi Goal * Validate surgical commercial opportunity for strategic ‘optio
Slide 18: Safety drives the applications
Safety drives the applications Sparing of connective tissue, vessels and nerves * Not impacted by heat sinks : ee cardiac synchronization ‘onc to regulated cell death (OD) Pulse Biosciences: Present priority Future potential scope Surgical Catheter (Open, Endoscopic, Percutaneous) (Endovascular, End
Slide 19: Robust IP Portfolio
Robust IP Portfolio Multipronged Patent Strategy 135 = feetedinsten tts (evel hy nanosecond a in biology owned & licensed Continued development and patent filings cove systems, Pate TREO ing nanosecond pulsing with other biological technologies and agents Patent Pending ‘Applications Patent Portfoli
Slide 20: Pulse Biosciences summary
Pulse Biosciences’ Inventors and Sole Manufacturers Robust IP Portfolio Across Unique Bioelectric Mechanism of of Unique Nanosecond Pulsed Nanosecond Pulse Technology Action with Game-Changing Electric Field Technology and System Cardiology Applications Extensive Medical Device Leverageable System A
Pulse Biosciences — Investor Presentation (July 2023) on 6ix